Based on our initial study and the hypothesis that immune responses would be superior in patients with a lower tumor burden, we initiated a follow up pilot study of the VRP-CEA(6D) in patients with resected stage III colorectal cancer who had completed standard adjuvant chemotherapy (fluoropyrimidine with or without oxaliplatin) but had no evidence of disease, yet an increased risk of recurrence [7]. This evidence concerns the gene CEACAM5 and neoplasm.